Acute behavioural effects of bupropion and naltrexone, alone and in combination, in non-deprived male rats presented with palatable mash

Psychopharmacology

Volumn 228, Issue 2, 2013, Pages 291-307

  Wright, F L ^a   Rodgers, R J ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Anorexia; Behavioural satiety sequence; Bupropion; Co treatment; Food intake; Naltrexone; Psychomotor stimulation; Rats

Indexed keywords

AMFEBUTAMONE; NALTREXONE;

ANIMAL EXPERIMENT; ARTICLE; BEHAVIOURAL SATIETY SEQUENCE; CONTROLLED STUDY; DRUG EFFECT; DRUG RESPONSE; EATING; FEEDING BEHAVIOR; FOOD INTAKE; HABITUATION; MALE; NONHUMAN; PRIORITY JOURNAL; PSYCHOMOTOR ACTIVITY; RAT; SATIETY; VIDEORECORDING; WEIGHT GAIN;

ANIMALS; BEHAVIOR, ANIMAL; BUPROPION; DOPAMINE UPTAKE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; EATING; MALE; NALTREXONE; NARCOTIC ANTAGONISTS; RATS; SATIETY RESPONSE; VIDEO RECORDING;

EID: 84879958216     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-013-3036-6     Document Type: Article

References (87)

1. Anderson JW, Greenway FL, Fujioka K et al (2002) Bupropion SR enhances weight loss: a 48-week double-blind, placebo-controlled trial. Obes Res 10:633-641
2. Apfelbaum M, Mandenhoff A (1981) Naltrexone suppresses hyperphagia induced in the rat by a highly palatable diet. Pharmacol Biochem Behav 15:89-91
3. Ascher JA, Cole JO, Colin JN et al (1995) Bupropion: a review of its mechanisms of antidepressant activity. J Clin Psychiatry 56:395-401
4. Berridge KC (2009) 'Liking' and 'wanting' food rewards: brain substrates and roles in eating disorders. Physiol Behav 97:537-550
5. Berridge KC, Ho C-Y, Richard JM, DiFeliceantonio AG (2010) The tempted brain eats: pleasure and desire circuits in obesity and eating disorders. Brain Res 1350:43-64
6. Billes SK, Cowley MA (2007) Inhibition of dopamine and norepinephrine reuptake produces additive effects on energy balance in lean and obese mice. Neuropsychopharmacology 32:822-834
7. Billes SK, Cowley MA (2008) Catecholamine reuptake inhibition causes weight loss by increasing locomotor activity and thermogenesis. Neuropsychopharmacology 33:1287-1297
8. Blumberg H, Dayton HB, Wolf PS (1967) Analgesic and narcotic antagonist properties of noroxymorphone derivatives. Toxicol Appl Pharmacol 10:406
9. Blundell JE, McArthur RA (1981) Behavioural flux and feeding: continuous monitoring of food intake and food selection, and the video-recording of appetitive and satiety sequences for the analysis of drug action. In: Garattini S, Samanin R (eds) Anorectic agents: Mechanisms of action and tolerance. Raven, New York, pp 19-43
10. Blundell JE, Rogers PJ, Hill AJ (1985) Behavioural structure and mechanisms of anorexia: calibration of natural and abnormal inhibition of eating. Brain Res Bull 15:371-376
11. Bodnar RJ (2004) Endogenous opioids and feeding behavior: a 30-year historical perspective. Peptides 25:697-725
12. Carrasco MC, Vicens P, Vidal J et al (2004) Effects of acute administration of bupropion on behavior in the elevated plus-maze test by NMRI mice. Prog Neuro-Psychopharmacol Biol Psychiatry 28:1135-1141
13. Chien CC, Lee YJ, Fan LW, Ho IK, Tien LT (2012) Naloxonazine, a specific mu-opioid receptor antagonist, attenuates the increment of locomotor activity induced by acute methamphetamine in mice. Toxicol Lett 212:61-65
14. Contrave NDA (2010) Available at http://www.fda.gov/downloads/ advisorycommittees/committeesmeetingmaterials/drugs/ endocrinologicandmetabolicdrugsadvisorycommittee/ucm235671.pdf
15. Cooper SJ (2004) Endocannabinoids and food consumption: comparisons with benzodiazepine and opioid palatability-dependent appetite. Eur J Pharmacol 500:37-49
16. Cooper SJ, Turkish S (1989) Effects of naltrexone on food preference and concurrent behavioral responses in food deprived rats. Pharmacol Biochem Behav 33:17-20
17. Cooper SJ, van der Hoek GA (1993) Cocaine: a microstructural analysis of its effects on feeding and associated behaviour in the rat. Brain Res 608:45-51
18. Cooper BR, Hester TJ, Maxwell RA (1980) Behavioral and biochemical effects of the antidepressant bupropion (Wellbutrin): evidence for selective blockade of dopamine uptake in vivo. J Pharmacol Expt Ther 215:127-431
19. Cooper SJ, Jackson A, Kirkham TC, Turkish S (1988) Endorphins, opiates and food intake. In: Rodgers RJ, Cooper SJ (eds) Endorphins, opiates and behavioural processes. Wiley, Chichester, pp 143-186
20. Cota D, Tschop MH, Horvath TL, Levine AS (2006) Cannabinoids, opioids and eating behavior: the molecular face of hedonism? Brain Res Rev 51:85-107
21. Dwoskin LP, Rauhut AS, King-Pospisil KA et al (2006) Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent. CNS Drug Rev 12:178-207
22. Fava M, Rush AJ, Thase ME et al (2005) 15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL. Prim Care Companion J Clin Psychiatry 7:106-113
23. Ferris RM, Cooper BR, Maxwell RA (1983) Studies of bupropion's mechanism of antidepressant action. J Clin Psychiatry 44:74-78
24. Gadde KM, Parker CB, Maner LG et al (2001) Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women. Obes Res 9:544-551
25. Goldstein A, Naidu A (1989) Multiple opioid receptors: legend selectivity profiles and binding site signatures. Mol Pharmacol 36:265-272
26. Gomez C, Carrasco C, Redolat R (2008) Effects of bupropion, alone or coadministered with nicotine, on social behavior in mice. Addict Biol 13:301-309
27. Greenway FL, Whitehouse MJ, Guttadauria M et al (2009) Rational design of a combination medication for the treatment of obesity. Obesity 17:30-39
28. Greenway FL, Fujioka K, Plodowski RA et al (2010) Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multi-centre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 376:595-605
29. Hadjimarkou MM, Singh A, Kndov Y, Israel Y, Pan Y-X, Rossi GC, Pasternak GW, Bodnar RJ (2004) Opioid involvement in food deprivation-induced feeding: evaluation of selective antagonist and antisense oligodeoxynucleotide probe effects in mice and rats. J Pharmacol Exp Ther 311:1188-1202
30. Halford JCG, Wanninayake SCD, Blundell JE (1998) Behavioural satiety sequence (BSS) for the diagnosis of drug action on food intake. Pharmacol Biochem Behav 61:159-168
31. Halford JCG, Boyland EJ, Blundell JE et al (2010) Pharmacological management of appetite expression in obesity. Nature Revs Endocrinol 6:255-269
32. Harrold JA, Dovey TM, Blundell JE, Halford JCG (2012) CNS regulation of appetite. Neuropharmacology 63:3-17
33. Heal DJ, Gosden J, Smith SL (2009) Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders. Br J Clin Pharmacol 68:861-874
34. Heal DJ, Gosden J, Smith SL (2012) What is the prognosis for new centrally-acting anti-obesity drugs? Neuropharmacology 63:132-146
35. Holtzman SG (1974) Behavioral effects of separate and combined administration of naloxone and d-amphetamine. J Pharmacol Exp Ther 189:51-60
36. Horst WD, Preskorn SH (1998) Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion. J Affect Disord 51:237-254
37. Ishii Y, Blundell JE, Halford JCG et al (2003) Effects of systematic variation in presatiation and fasting on the behavioural satiety sequence in male rats. Physiol Behav 79:227-238
38. Jackson HC, Sewell RDE (1985a) Are δ-opioid receptors involved in the regulation of food and water intake? Neuropharmacology 24:885-888
39. Jackson HC, Sewell RDE (1985b) Involvement of endogenous enkephalins in the feeding response to diazepam. Eur J Pharmacol 107:389-391
40. Jain AK, Kaplan RA, Gadde KM et al (2002) Bupropion SR vs placebo for weight loss in obese patients with depressive symptoms. Obes Res 10:1049-1056
41. Kennett GA, Clifton PG (2010) New approaches to the pharmacological treatment of obesity: can they break through the efficacy barrier? Pharmacol Biochem Behav 97:63-83
42. Kirkham TC, Blundell JE (1984) Dual action of naloxone on feeding revealed by behavioural analysis: separate effects on initiation and termination of eating. Appetite 5:45-52
43. Kirkham TC, Blundell JE (1986a) Effect of naloxone and naltrexone on the development of satiation measured in the runway: comparisons with d-amphetamine and d-fenfluramine. Pharmacol Biochem Behav 25:123-128
44. Kirkham TC, Blundell JE (1986b) Opioid antagonist effects on feeding observed in the runway. Neuropharmacology 25:649-651
45. Kirkham TC, Blundell JE (1987) Effects of naloxone and naltrexone on meal patterns of freely-feeding rats. Pharmacol Biochem Behav 26:515-520
46. Kirkham TC, Barber DJ, Heath RW, Cooper SJ (1987) Differential effects of CGS8216 and naltrexone on ingestional behaviour. Pharmacol Biochem Behav 26:145-151
47. Li Z, Maglione M, Tu W et al (2005) Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med 142:532-546
48. Liu Y-L, Connoley IP, Harrison J et al (2002) Comparison of the thermogenic and hypophagic effects of sibutramine's metabolite 2 and other monoamine reuptake inhibitors. Eur J Pharmacol 452:49-56
49. Magnan J, Paterson SJ, Tavani A, Kosterlitz HW (1982) The binding spectrum of narcotic analgesic drugs with different agonist and antagonist properties. Naunyn-Schmied Arch Pharmacol 316:197-205
50. Marks-Kaufman R, Plager A, Kanarek RB (1985) Central and peripheral modifications of endogenous opioid systems to nutrient selection in rats. Psychopharmacology 85:414-418
51. Martin WR, Wikler A, Eades CG, Pescor FT (1963) Tolerance to and physical dependence on morphine in rats. Psychopharmacology 4:247-260
52. Miller DK, Wong EHF, Chesnut MD et al (2002) Reboxetine: functional inhibition of monoamine transporters and nicotinic acetylcholine receptors. J Pharmacol Exp Ther 302:687-695
53. Nielsen JA, Shannon NJ, Bero L et al (1986) Effects of acute and chronic bupropion on locomotor activity and dopaminergic neurons. Pharmacol Biochem Behav 24:795-799
54. Padwal R (2009) Contrave, a bupropion and naltrexone combination therapy for the potential treatment of obesity. Curr Opin Invest Drugs 10:1117-1125
55. Paterson NE, Fedolak A, Olivier B et al (2010) Psychostimulant-like discriminative stimulus and locomotor sensitization properties of the wake-promoting agent modafanil in rodents. Pharmacol Biochem Behav 95:449-456
56. Raynor K, Kong H, Chen Y, Yasuda K, Yu L, Bell GI, Reisine T (1994) Pharmacological characterization of the cloned κ-, δ-, and μ-opioid receptors. Mol Pharmacol 45:330-334
57. Redolat R, Gomez MC, Vicens et al (2005a) Bupropion effects on aggressiveness and anxiety in OF1 male mice. Psychopharmacology 177:418-427
58. Redolat R, Vidal J, Gomez MC et al (2005b) Effects of acute bupropion administration on locomotor activity in adolescent and adult mice. Behav Pharmacol 16:59-62
59. Rodgers RJ, Holch P, Tallett AJ (2010) Behavioural satiety sequence (BSS): separating wheat from chaff in the behavioural pharmacology of appetite. Pharmacol Biochem Behav 97:3-14
60. Rodgers RJ, Tschöep MH, Wilding JPH (2012) Anti-obesity drugs: past, present and future. Dis Model Mech 5:621-626
61. Roth JD, Trevaskis JL, Turek VF, Parkes DG (2010) 'Weighing in' on synergy: preclinical research on neurohumoral anti-obesity combinations. Brain Res 1350:86-94
62. Sanger DJ, McCarthy PS (1982) A comparison of the effects of opiate antagonists on operant and ingestive behavior. Pharmacol Biochem Behav 16:1013-1015
63. Santamaria A, Arias HR (2010) Neurochemical and behavioral effects elicited by bupropion and diethylpropion in rats. Behav Brain Res 211:132-139
64. Slemmer JE, Martin BR, Damaj MI (2000) Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther 295:321-327
65. Soroko FE, Mehta NB, Maxwell RA et al (1977) Bupropion hydrochloride ((±) α-t-butylamino-3-chloropropiophenone HCl): a novel antidepressant agent. J Pharm Pharmacol 29:767-770
66. Stairs DJ, Dworkin SI (2008) Rate-dependent effects of bupropion on nicotine self-administration and food-maintained responding in rats. Pharmacol Biochem Behav 90:701-711
67. Suckow RF, Smith TM, Perumai AS et al (1986) Pharmacokinetics of bupropion and metabolites in plasma and brain of rats, mice, and guinea pigs. Drug Metab Dis 14:692-697
68. Tallett AJ, Blundell JE, Rodgers RJ (2007) Grooming, scratching and feeding: role of response competition in acute anorectic response to rimonabant in male rats. Psychopharmacology 195:27-39
69. Tallett AJ, Blundell JE, Rodgers RJ (2008a) Endogenous opioids and cannabinoids: system interactions in the regulation of appetite, grooming and scratching. Physiol Behav 94:422-431
70. Tallett AJ, Blundell JE, Rodgers RJ (2008b) Behaviourally-selective hypophagic effects of naloxone in non-deprived male rats presented with palatable food. Behav Brain Res 187:417-427
71. Tallett AJ, Blundell JE, Rodgers RJ (2009a) Effects of acute low dose combined treatment with naloxone and AM 251 on food intake, feeding behaviour and weight gain in rats. Pharmacol Biochem Behav 91:358-366
72. Tallett AJ, Blundell JE, Rodgers RJ (2009b) Night and day: diurnal differences in the behavioural satiety sequence in male rats. Physiol Behav 97:125-130
73. Tepperman FS, Hirst M, Smith P (1983) Brain and serum levels of naloxone following peripheral administration. Life Sci 33:1091-1096
74. Tucci SA, Halford JCG, Harrold JA et al (2006) Therapeutic potential of targeting the endocannabinoids: implications for the treatment of obesity, metabolic syndrome, drug abuse and smoking cessation. Current Med Chem 13:2669-2680
75. van Rossum JM, Simons F (1969) Locomotor activity and anorexogenic action. Psychopharmacologia (Berl) 14:248-254
76. Vickers SP, Clifton PG (2012) Animal models to explore the effects of CNS drugs on food intake and energy expenditure. Neuropharmacology 63:124-131
77. Vickers SP, Jackson HC, Cheetham SC (2011) The utility of animal models to evaluate novel anti-obesity agents. Br J Pharmacol 164:1248-1262
78. Wadden TA, Foreyt JP, Foster GD, Hill JO, Klein S, O'Neill PM, Perri MG, Pi-Sunyer FX, Rock CL, Erickson JS, Mair HN, Kim DD, Dunayevich E (2011) Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity 19:110-120
79. Warner C, Shoaib M (2005) How does bupropion work as a smoking cessation aid? Addict Biol 10:219-231
80. Weiss SM (1995) Pharmacological and behavioural examination of the defensive reactions of laboratory mice to the calls of the tawny owl. Ph.D. thesis, School of Psychology, University of Leeds, UK
81. Wiskerke J, Schetters D, van Es IE, van Mourik Y, den Hollander BR, Schoffelmeer AN, Pattij T (2011) μ-Opioid receptors in the nucleus accumbens shell region mediate the effects of amphetamine on inhibitory control but not impulsive choice. J Neurosci 31:262-272
82. Wright FL, Rodgers RJ (2012) Low dose naloxone attenuates the pruritic but not anorectic response to rimonabant in male rats. Psychopharmacology. doi: 10.1007/s00213-012-2916
83. Yeomans MR, Gray RW (2002) Opioid peptides and the control of human ingestive behaviour. Neurosci Biobehav Rev 26:713-728
84. Young AA (2012) Brainstem sensing of meal-related signals in energy homeostasis. Neuropharmacology 63:31-45
85. Zarrindast MR, Hosseini-Nia T (1988) Anorectic and behavioural effects of bupropion. Gen Pharmac 19:201-204
86. Zarrindast MR, Hodjati MR, Pejhan A et al (1996) Bupropion induces sniffing: a possible dopaminergic mechanism. Eur Neuropsychopharmacol 6:299-303
87. Zimmerman M, Posternak MA, Attiullah N et al (2005) Why isn't bupropion the most frequently prescribed antidepressant? J Clin Psychiatry 66:603-610